Company Analysis

Nektar Therapeutics (NKTR)

Nasdaq: NKTR · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1996
Grade4.3
◀ Past 4.0● Present 4.8▶ Future 4.0
1 est.

Who runs Nektar Therapeutics

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Robin Howard W
President & CEO. First filing Jan 2007, latest Aug 20, 2026, 64 filings in all.
Officers reporting now
5
of 9 people with a filing in the last fifteen months
Directors reporting now
4
23 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Chess RobertChairman of the BoardFeb 2006Sep 25, 2026none
Robin Howard WPresident & CEOJan 2007Aug 20, 20268 · $1.4M
Zalevsky JonathanChief R&D OfficerOct 2019Aug 20, 20267 · $1.0M
Rubinstein Linda MInterim CFOMay 2026May 26, 2026none
Wilson Mark AndrewChief Legal OfficerApr 2020Nov 25, 20251 · $0.00
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Ajer Jeffrey RobertdirectorSep 2017Sep 25, 2026none
Brainard DianadirectorNov 2021Sep 25, 2026none
Greer R ScottdirectorFeb 2010Sep 25, 2026none
Whitfield Roy AdirectorSep 2006Sep 25, 2026none
Earlier names on the record17, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton NKTR · research, not advice